Converting Theory into Practice

Executive Thesis Partners

Under the educational collaboration agreement pioneer in a business school our students will develop during our programmes projects and thesis based on real drug candidates. Over the years we have been working in the main therapeutics areas creating plans in oncology, central nervous system, rare disease, Dengue, among others.

Those projects are managed under confidentially and the objective is the interaction with the principal researcher, the technology transfer managers, and with the BBI coordinador and board of lectures in order to develop real plans to develop those drug candidates. 

Read more about the collaboration here PRESS RELEASE

Review our EDUCATIONAL MODEL based on real patents

Learn about the BBI CAREER IMPACT PROGRAMME 

EDUCATIONAL PARTNERS IN COLLABORATION AGREEMENT WITH THE BBI

 

Our educational method combines the theoretical classes and a MBA thesis to develop with our research center partners and their respective technology transfers offices.

 

That allow to our MBA candidates to understand the reality of the decision-making process to expand internationally new research lines, either due to licensing agreements or setting up the biotechnology-based company. 

Become part of the decision-making process of real case studies while you develop your international management skills


These are some of the projects that the BBI students have develop over the years in collaboration with the technology transfers officers, research centers and entrepreneurs.

  • No found img
    2022: Talisman Therapeutics is a neurodegenerative disease drug discovery company, based on the Babraham Research Campus in Cambridge UK.
    Talisman uses novel, proprietary human stem cell models of neurodegenerative disease. This enables rapid and relevant target identification and validation, as well as testing of candidate therapeutics. This approach significantly accelerates drug discovery.
    View PDF
    2022: Talisman Therapeutics is a neurodegenerative disease drug discovery company, based on the Babraham Research Campus in Cambridge UK.
    No found img
    Talisman uses novel, proprietary human stem cell models of neurodegenerative disease. This enables rapid and relevant target identification and validation, as well as testing of candidate therapeutics. This approach significantly accelerates drug discovery.
    View PDF
  • No found img
    2022: CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
    CIC bioGUNE, member of the Basque Research and Technology Alliance (BRTA), is a key research center within the national and international scientific landscape and has emerged as a knowledge source in the area of health science. The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry, Structural, Molecular and Cell Biology, with the aim of developing a more Precise Medicine for the future.
    View PDF
    2022: CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
    No found img
    CIC bioGUNE, member of the Basque Research and Technology Alliance (BRTA), is a key research center within the national and international scientific landscape and has emerged as a knowledge source in the area of health science. The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry, Structural, Molecular and Cell Biology, with the aim of developing a more Precise Medicine for the future.
    View PDF
  • No found img
    2021: Gate2Brain. A novel technology platform for the delivery of therapeutics across biological barriers
    Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.
    View PDF
    2021: Gate2Brain. A novel technology platform for the delivery of therapeutics across biological barriers
    No found img
    Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.
    View PDF
  • No found img
    2021: Integra Therapeutics. Engineering the next generation of gene editing tools to cure diseases.
    At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery. ​
    View PDF
    2021: Integra Therapeutics. Engineering the next generation of gene editing tools to cure diseases.
    No found img
    At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery. ​
    View PDF
  • No found img
    2021: Monument Therapeutics. Bringing Precision Medicine to Neuroscience Drug Development
    Monument Tx has a well-balanced pipeline that includes two independent programmes with different and substantial central nervous system indications each with a significant unmet medical need. Proprietary biomarkers developed by the Monument Tx team allows precise selection of the patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilising generic actives with a known safety profile or will expand the label of approved generics. The development plan for each programme permits rapid progress with early proof-of-concept data leading to Phase II clinical development.
    View PDF
    2021: Monument Therapeutics. Bringing Precision Medicine to Neuroscience Drug Development
    No found img
    Monument Tx has a well-balanced pipeline that includes two independent programmes with different and substantial central nervous system indications each with a significant unmet medical need. Proprietary biomarkers developed by the Monument Tx team allows precise selection of the patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilising generic actives with a known safety profile or will expand the label of approved generics. The development plan for each programme permits rapid progress with early proof-of-concept data leading to Phase II clinical development.
    View PDF
  • No found img
    2020: A new therapy for breast tumours based on genomic characteristics
    p38MAM is a new therapeutic approach for breast cancer patients based on modulation of the genomic integrity of cancer cells. The therapeutic effect is based on the combination of a chemotherapeutic drug and a p38 inhibitor. p38MAM gains strong relevance, for the triple-negative breast cancer subtype, against which there is no directed therapy. p38MAM will be also applicable for predicting the prognosis of treatments and selecting patients for new clinical assays.
    View PDF
    2020: A new therapy for breast tumours based on genomic characteristics
    No found img
    p38MAM is a new therapeutic approach for breast cancer patients based on modulation of the genomic integrity of cancer cells. The therapeutic effect is based on the combination of a chemotherapeutic drug and a p38 inhibitor. p38MAM gains strong relevance, for the triple-negative breast cancer subtype, against which there is no directed therapy. p38MAM will be also applicable for predicting the prognosis of treatments and selecting patients for new clinical assays.
    View PDF
  • No found img
    2020: βPFO A novel and promising new target against Alzheimer's disease
    βPFO is a novel amyloid-β (Aβ) oligomer preparation, which can be used to screen for new drugs against Alzheimer’s Disease (AD). βPFO forms in an in-vitro membrane-mimicking environment and comprises an homogeneous population of β-barrel pore-forming Aβ oligomers. βPFO results from extensive research experience on protein aggregation, combined with an exhaustive screening of various physicochemical conditions that mimic a membrane environment.
    View PDF
    2020: βPFO A novel and promising new target against Alzheimer's disease
    No found img
    βPFO is a novel amyloid-β (Aβ) oligomer preparation, which can be used to screen for new drugs against Alzheimer’s Disease (AD). βPFO forms in an in-vitro membrane-mimicking environment and comprises an homogeneous population of β-barrel pore-forming Aβ oligomers. βPFO results from extensive research experience on protein aggregation, combined with an exhaustive screening of various physicochemical conditions that mimic a membrane environment.
    View PDF
  • No found img
    2020: A new validated HTS to identify new first-in-class antitumoral compounds
    Stress-activated protein kinases, as p38, play a key role in controlling different cellcycle checkpoints. RB phosphorylation by p38 caused an increase of RB affinity to E2F transcription factors, which in turn leads to cyclin expression down-regulation and reduction of cell proliferation. The N- terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells. We have developed and validate a HTS system to identify small compounds capable of mimicking the Nterm RB phosphorylation for therapeutic applications as new anticancer compounds.
    View PDF
    2020: A new validated HTS to identify new first-in-class antitumoral compounds
    No found img
    Stress-activated protein kinases, as p38, play a key role in controlling different cellcycle checkpoints. RB phosphorylation by p38 caused an increase of RB affinity to E2F transcription factors, which in turn leads to cyclin expression down-regulation and reduction of cell proliferation. The N- terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells. We have developed and validate a HTS system to identify small compounds capable of mimicking the Nterm RB phosphorylation for therapeutic applications as new anticancer compounds.
    View PDF
  • No found img
    2019: Novel set of markers to select active adipose stem cells (ACS) for improving efficacy of cell therapy
    Cell therapy with mesenchymal stem cells (MSCs) has been described as a promising clinical strategy for regenerative medicine due to their immunosuppressive and tissue repair properties. Adipose tissue is an important source of this cell type (named ASCs) since they are more potent in terms of immunomodulation than their bone marrow counterparts.
    View PDF
    2019: Novel set of markers to select active adipose stem cells (ACS) for improving efficacy of cell therapy
    No found img
    Cell therapy with mesenchymal stem cells (MSCs) has been described as a promising clinical strategy for regenerative medicine due to their immunosuppressive and tissue repair properties. Adipose tissue is an important source of this cell type (named ASCs) since they are more potent in terms of immunomodulation than their bone marrow counterparts.
    View PDF
  • No found img
    2019: Portable device for molecular diagnosis (PDMP)
    A research group, with wide experience on microelectronics and on the development of measure and image system, has generated a portable device for a low-cost molecular diagnosis based on the measurement of samples’ fluorescence. The PDMD uses the fluorescence lifetime measurement in the samples to carry out fast diagnostic tests through label detection.
    View PDF
    2019: Portable device for molecular diagnosis (PDMP)
    No found img
    A research group, with wide experience on microelectronics and on the development of measure and image system, has generated a portable device for a low-cost molecular diagnosis based on the measurement of samples’ fluorescence. The PDMD uses the fluorescence lifetime measurement in the samples to carry out fast diagnostic tests through label detection.
    View PDF
  • No found img
    2018: Onco-Selec Oncoselective mechanism for gene or viral therapy
    ONCO-SELEC is a new tool designed to fight cancer. It is based on a novel mechanism that may be applied in optimising the efficacy of genetic therapies. It works by providing full oncolytic potency of the cytotoxic gene when in cancer cells and, at the same time, producing attenuation of the same cytotoxic gene, in normal ones. This system will improve both safety and efficacy of gene and viral based therapies.
    View PDF
    2018: Onco-Selec Oncoselective mechanism for gene or viral therapy
    No found img
    ONCO-SELEC is a new tool designed to fight cancer. It is based on a novel mechanism that may be applied in optimising the efficacy of genetic therapies. It works by providing full oncolytic potency of the cytotoxic gene when in cancer cells and, at the same time, producing attenuation of the same cytotoxic gene, in normal ones. This system will improve both safety and efficacy of gene and viral based therapies.
    View PDF
  • No found img
    2017: MAXPHOX Novel cost saving catalysts for asymmetric hyrogenation of enamides
    The Research Unit on Asymmetric Synthesis of IRB Barcelona has developed MAXPHOX, a new series of ligands capable of increasing the enantiomeric excess of certain asymmetric hydrogenation reactions up to a 99%ee (enantiomeric excess), using both low H2 pressure and temperature. As an example, a member of the MAXPHOX family widely improves the current synthesis of Rotigotine from an 84 to a 99%ee, using 3 bar pressure.
    View PDF
    2017: MAXPHOX Novel cost saving catalysts for asymmetric hyrogenation of enamides
    No found img
    The Research Unit on Asymmetric Synthesis of IRB Barcelona has developed MAXPHOX, a new series of ligands capable of increasing the enantiomeric excess of certain asymmetric hydrogenation reactions up to a 99%ee (enantiomeric excess), using both low H2 pressure and temperature. As an example, a member of the MAXPHOX family widely improves the current synthesis of Rotigotine from an 84 to a 99%ee, using 3 bar pressure.
    View PDF
CHECK OUT SOME OF THE COMPANIES THAT HAVE BEEN WORKING DURING OUR GLOBAL MBAS AND HAVE BEEN PART OF THE ANNUAL THESIS

FAQs

Here are some of the most frequent questions from our candidates

The Worldwide Business School for Life Sciences